Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies

Recruiting Phase 1 Phase 2 Interventional Study
T-cell Acute Lymphoblastic Leukemia Acute Lymphoblastic Leukemia, in Relapse Refractory Acute Lymphoblastic Leukemia T-cell Malignancies
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
1 – 70
Sex
Any
Trial phase
Phase 1/2
Study type
Interventional
Purpose
Treatment
Participants needed
80 (estimated)
Sponsor
Beijing GoBroad Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This is a multi-center, open-label, non-randomized, phase I/II trial. Patients with refractory or relapsed T-cell malignancies will receive autologous, prior-HSCT donor-derived or new donor-derived CD7 CAR T cells according to their HSCT history, peripheral blood leukemia burden and at their discretion. The primary objective is to learn about the safety of autologous, prior-HSCT donor-derived and …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Only patients who meet all the following criteria can be included in the group: 1. CD7-positive refractory or relapsed T-cell malignancies with progression or intolerance after all standard treatments, limited prognosis from currently available treatments and no available treat…
Contacts

zhuojun ling

86+18611422920

lingzj@gobroadhealthcare.com

CONTACT